Evidence map›Paper›PMID 36252035›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Disruption of proteostasis causes IRE1 mediated reprogramming of alveolar epithelial cells.

Jeremy Katzen, Luis Rodriguez, Yaniv Tomer, Apoorva Babu, Ming Zhao, Aditi Murthy, Paige Carson, Matthew Barrett, Maria C Basil, Justine Carl and 8 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis.Seminars in respiratory and critical care medicine · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Jeremy KatzenDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.ORCID 0000-0001-9208-7729
Luis RodriguezDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.ORCID 0000-0001-7176-0697
Yaniv TomerDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.
Apoorva BabuPenn-Children's Hospital of Philadelphia Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, 19104.
Ming ZhaoDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.ORCID 0000-0001-5415-0715
Aditi MurthyDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.
Paige CarsonDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.
Matthew BarrettDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.
Maria C BasilDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.ORCID 0000-0003-4716-1285
Justine CarlPenn-Children's Hospital of Philadelphia Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, 19104.
John P LeachPenn-Children's Hospital of Philadelphia Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, 19104.
Michael MorleyPenn-Children's Hospital of Philadelphia Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, 19104.
Matthew D McGrawDivision of Pulmonology, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, 14642.
Surafel MulugetaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.
Timothy PeluraOptiKira, Beachwood, OH, 44122.
Glenn RosenOptiKira, Beachwood, OH, 44122.
Edward E MorriseyPenn-Children's Hospital of Philadelphia Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, 19104.
Michael F BeersDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA,19104.ORCID 0000-0002-2149-3209
University of Pennsylvania · USChildren's Hospital of Philadelphia · USUniversity of Rochester Medical Center · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Editing Alveolar Progenitor Cells for Correction of Monogenic DiseaseU01HL134745 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTON, DARRELL N., MORRISEY, EDWARD E · 2016 to 2022
$8.3M
Wnt signaling in the alveolar nicheR01HL087825 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MORRISEY, EDWARD E · 2008 to 2021
$6.4M
Molecular pathways controlling alveolar epithelial remodeling in development and regenerationR01HL132999 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MORRISEY, EDWARD E · 2016 to 2023
$4.6M
Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular TargetsR01HL145408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MICHAEL FRANCIS BEERS · 2019 to 2026
$4.6M
Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary FibrosisU01HL152970 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BEERS, MICHAEL FRANCIS · 2021 to 2024
$3.0M
Transcriptional Regulation of Lung Alveolar RegenerationR01HL152194 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MORRISEY, EDWARD E · 2021 to 2024
$2.3M
Mechanisms of Basal Cell Dysfunction in Chemical-induced Bronchiolitis ObliteransK08ES033290 · NIEHS · UNIVERSITY OF ROCHESTER · PI MCGRAW, MATTHEW DANIEL · 2022 to 2025
$936k
Understanding how alveolar epithelial cell stress drives aberrant repair in interstitial lung diseaseK08HL150226 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KATZEN, JEREMY BINDER · 2020 to 2024
$840k
Molecular regulation of cell fate and progenitor function in the distal human respiratory airwaysK08HL163398 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Maria Ciocca Basil · 2022 to 2026
$834k
COVID-19: Understanding The Role of Corona Virus InducedDisruption Of Alveolar Type 2 Cell Function And SurfactantHomeostasis In The Pathogenesis Of COVID-19 AcuteRespiratory Distress SyndromeI01BX005411 · VA · PHILADELPHIA VA MEDICAL CENTER · PI BEERS, MICHAEL FRANCIS · 2021 to 2023
–
Surfactant Protein C Mutations and Interstitial Lung DiseaseI01BX001176 · VA · PHILADELPHIA VA MEDICAL CENTER · PI MICHAEL FRANCIS BEERS · 2012 to 2026
–
BLRD VA I01 BX001176BLRD VA I01 BX005411NHLBI NIH HHS K08 HL150226NHLBI NIH HHS K08 HL163398NHLBI NIH HHS R01 HL087825NHLBI NIH HHS R01 HL132999NHLBI NIH HHS R01 HL145408NHLBI NIH HHS R01 HL152194NHLBI NIH HHS U01 HL134745NHLBI NIH HHS U01 HL152970NIEHS NIH HHS K08 ES033290NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Disruption of alveolar type 2 cell (AEC2) protein quality control has been implicated in chronic lung diseases, including pulmonary fibrosis (PF). We previously reported the in vivo modeling of a clinical surfactant protein C (SP-C) mutation that led to AEC2 endoplasmic reticulum (ER) stress and spontaneous lung fibrosis, providing proof of concept for disruption to proteostasis as a proximal driver of PF. Using two clinical SP-C mutation models, we have now discovered that AEC2s experiencing significant ER stress lose quintessential AEC2 features and develop a reprogrammed cell state that heretofore has been seen only as a response to lung injury. Using single-cell RNA sequencing in vivo and organoid-based modeling, we show that this state arises de novo from intrinsic AEC2 dysfunction. The cell-autonomous AEC2 reprogramming can be attenuated through inhibition of inositol-requiring enzyme 1 (IRE1α) signaling as the use of an IRE1α inhibitor reduced the development of the reprogrammed cell state and also diminished AEC2-driven recruitment of granulocytes, alveolitis, and lung injury. These findings identify AEC2 proteostasis, and specifically IRE1α signaling through its major product XBP-1, as a driver of a key AEC2 phenotypic change that has been identified in lung fibrosis.

Indexed as

Alveolar Epithelial CellsCellular ReprogrammingLung InjuryMembrane ProteinsProtein Serine-Threonine KinasesPulmonary FibrosisEndoplasmic Reticulum StressEndoribonucleasesInositolProteostasisPulmonary Surfactant-Associated Protein CEndoribonucleasesErn2 protein, mouseInositolMembrane ProteinsProtein Serine-Threonine KinasesPulmonary Surfactant-Associated Protein CER stressquality controlsurfactant protein Ctransitional cellunfolded protein response

Identifiers

PMID36252035
PMCPMC9618079
OpenAlexW4306641824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.